Clinical trials: Thymalfasin
Carcinoma, Pancreatic Ductal
Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC
This is a prospective, single-center, single-arm, phase II clinical study. The primary purpose of the study was to evaluate the efficacy and safety of radiotherapy with sequential albumin-bound paclitaxel + Gemcitabine…
- Trial name
- NCT06573398
- Testing
- SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Colorectal Cancer, Metastatic Colorectal Cancer
Abscopal Effect for Metastatic Colorectal Cancer
Patients with colorectal cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1.
- Conditions
- Colorectal Cancer, Metastatic Colorectal Cancer, Thymalfasin
- Trial name
- NCT02535988
- Testing
- Radiation therapy, Thymalfasin
- Sponsor
- Zhejiang Provincial People's Hospital
Severe Sepsis
Efficacy of Thymosin alpha1 for Severe Sepsis
The purpose of this study is to evaluate the efficacy of thymosin alpha 1 for treating severe sepsis.
- Trial name
- ETASS (NCT00711620)
- Testing
- Thymosin alpha 1
- Where
- China
- Volunteers
- 366 people
- Sponsor
- Sun Yat-sen University
Sepsis, Immunosuppression
Thymalfasin for Immune Recovery in Adults With Sepsis
Sepsis is a life-threatening illness caused by an abnormal response to infection. Some people with sepsis have reduced immune function, which may make recovery more difficult.
- Trial name
- RAISE (NCT07866118)
- Testing
- Thymalfasin (Thymosin alpha 1, Ta1)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Zhongshan Hospital
Non-small Cell Lung Cancer
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
This prospective phase II randomized study is to determine the impact of thymosin alpha-1 on the concurrent chemoradiotherpay followed by immunotherapy consolidation in patients with locally advanced NSCLC by assessing the…
- Trial name
- NCT06139419
- Testing
- definitive radiotherapy, induction chemo-immunotherapy, concurrent chemotherapy
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Sun Yat-sen University
Non-Small Cell Lung Cancer
Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type
Thymosin alpha 1 plus maintenance therapy with the Standard of Care (SoC) chemotherapy plus cisplatin (or carboplatin) in patients with metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR wild type
- Trial name
- NCT02906150
- Testing
- Thymalfasin (Thymosin alpha 1, Ta1), SoC (chemotherapy and platinum agent)
- Where
- 8 sites in Italy
- Volunteers
- 140 people
- Sponsor
- SciClone Pharmaceuticals
Sepsis
Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis
The purpose of this study is to determine whether thymosin alpha 1 is effective on improving monocyte function and has the desired pharmacologic activity for sepsis
- Trial name
- NCT02883595
- Testing
- thymosin alpha 1
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
Resectable Non-Small-Cell Lung Cancer
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
This study aims to explore the efficacy and safety of thymosin α-1 (Tα1) plus chemotherapy and PD-1 inhibitors as neoadjuvant therapy for operable non-small cell lung cancer
- Trial name
- NCT06607926
- Testing
- Thymosin Alpha 1, Tislelizumab, Platinum-doublet chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xuanwu Hospital, Beijing
Chronic Hepatitis C
Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.
The purpose of the study was to determine safety and efficacy of 48 weeks treatment with Thymosin alpha 1 (Talpha1) in combination with pegylated interferon (PEGIFN) alpha2a and ribavirin (RBV) in adult patients with chronic…
- Trial name
- NCT01178996
- Testing
- Thymosin alpha 1, Ribavirin, PEGinterferon alfa2a
- Where
- 9 sites in France, Germany and 3 more
- Volunteers
- 552 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Non Small Cell Lung Cancer
Immuno-effect of Tα1 for Stage I NSCLC
To explore the effect of thymosin alpha 1 (Tα1) on postoperative peripheral blood circulating tumor cells and immunosenescence in patients with early-stage non-small cell lung cancer (NSCLC).
- Trial name
- NCT06598839
- Testing
- Thymosin Alpha1
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yousheng Mao
Esophageal Cancer, Metastatic Esophageal Cancer
SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer
Patients with esophageal cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1.
- Conditions
- Esophageal Cancer, Metastatic Esophageal Cancer, Stereotactic Body Radiation Therapy, Thymalfasin
- Trial name
- NCT02545751
- Testing
- Stereotactic Body Radiation Therapy, Thymalfasin
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Hangzhou Cancer Hospital
Colorectal Neoplasms
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer
It is a single-center, retrospective, controlled study to investigate the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin for locally advanced mid-low rectal cancer.
- Trial name
- NCT06024356
- Testing
- Thymalfasin
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Beijing Friendship Hospital
END STAGE RENAL DISEASE
A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine
The purpose of this explorative trial is to collect preliminary data on efficacy and safety of thymosin alpha 1 given at different doses as an adjuvant to egg-derived H1N1sw monovalent influenza vaccine in hemodialysis patients.
- Trial name
- NCT01031966
- Testing
- MF59 adjuvanted H1N1 influenza monovalent vaccine, Thymosin alpha 1
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Lung Cancer Metastatic
SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy
The purpose of this study is to determine whether stereotactic body radiotherapy (SBRT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) and Thymosin Alpha 1 is safe, effective in the…
- Trial name
- NCT02976740
- Testing
- SBRT, Immunological Agent, Immunological Factors
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Advanced Solid Tumor, Refractory Tumor
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
This is an open-label, single-arm, Phase II investigator-initiated trial of precise thymalfasin-regulated therapy combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF for treatment of advanced…
- Trial name
- NCT05790447
- Testing
- Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Gastric Cancer, Esophagogastric Junction Adenocarcinoma
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
This Phase II clinical study is a prospective, open-label, single-arm trial designed to evaluate the efficacy and safety of combining anti-PD-1 therapy (Serplulimab) with thymalfasin and the SOX chemotherapy regimen as a…
- Trial name
- NCT06461910
- Testing
- Serplulimab, thymalfasin, Oxaliplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zekuan Xu
Hepatitis B, Chronic
Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B
This trial is to assess the efficacy and safety of Polyethylene Glycol thymosin alpha1 (PEG-Tα1), a new long immunomodulator (Category 1.1 of Chemical Drugs) being developed from Hansoh Pharmaceutical of China, in combination…
- Trial name
- PEG-Tα1 (NCT02366208)
- Testing
- PEG-Tα1, Adefovir
- Where
- 12 sites in China
- Volunteers
- 116 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
EGFR Mutation Positive Non Small Cell Lung Cancer
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
Phase I: evaluate the safety and tolerability two different dosing regimens of Thymosin alpha 1 in patients with advanced EGFR mutation positive NSCLC on Standard of Care (SoC) therapy.
- Trial name
- NCT02906163
- Testing
- Thymalfasin (Thymosin alpha 1, Ta1), SoC (tyrosine kinase inhibitor)
- Where
- 5 sites in Italy
- Volunteers
- 188 people
- Sponsor
- SciClone Pharmaceuticals
Vaccine Response, COVID-19 Vaccine
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
The goal of this research is to learn more about ZADAXIN® (trade name; thymalfasin generic; Ta1 for short) and determine if Ta1 has any benefit in increasing the immune response to the COVID-19 vaccine.
- Conditions
- Vaccine Response, COVID-19 Vaccine, Immune Response to Covid 19 Vaccination
- Trial name
- NCT06821100
- Testing
- Thymalfasin (Thymosin alpha 1, Ta1)
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
IrAE
Thymosin Alpha-1 for irAE Secondary to ICIs
Thymosin alpha-1 (Tα-1) has shown clinical benefits in patients whose immune functions are severely compromised or ineffective. Therefore, this study is attempted to explore whether Tα-1 could be used as a therapeutic option for…
- Trial name
- NCT06178146
- Testing
- Thymosin Alpha1, Immunosuppressant
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jun Wang